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Introduction: Isoniazid preventative therapy (IPT) is a widely used intervention for treatment 
of latent tuberculosis infection (LTBI), particularly in patients at high risk for reactivation. 
While treatment-limiting adverse effects have been well studied, few prospective studies have 
considered the range of adverse effects that patients may experience with IPT.
Methods: All patients commencing treatment for LTBI were prospectively enrolled in an 
ongoing database of LTBI treatment outcomes particularly related to adverse effects, treatment 
adherence, and treatment completion.
Results: Data on the first 100 patients who were prescribed IPT are presented. Fifty-six patients 
reported at least one adverse effect at some stage during treatment, with six experiencing at 
least one World Health Organization (WHO) Grade 3–4 adverse effect. Increased age was sig-
nificantly associated with risk of adverse effects (odds ratio [OR] =1.05 per year; confidence 
interval [CI] of 1.02–1.08=95%). Eighty-five patients had documented completion of therapy 
locally, with ten patients ceasing IPT due to adverse effects.
Discussion: This report highlights a variety of somatic adverse effects that occurred in a real-
world cohort of patients receiving IPT. While adverse effects were frequently identified in this 
study, the considerable majority were low grade and transient. Despite frequent adverse effects 
of LTBI in our treatment cohort, the study demonstrated high levels of treatment adherence 
and completion.
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Introduction
Isoniazid preventative therapy (IPT) is a widely-used intervention for treatment of 
latent tuberculosis infection (LTBI). Most commonly consisting of a 6- to 9-month 
course of daily isoniazid, the use of treatment to prevent tuberculosis infection has 
previously been focused on household contacts of those with active disease.1 However, 
in recent years, an expanding group of patients has been recognized as being at higher 
risk of LTBI reactivation. Patients within this group are receiving immunosuppres-
sive medications, especially tumor necrosis factor alpha (TNF-α) inhibitors, and are 
routinely recommended IPT prior to the initiation of therapy.2
Given the increasing number of patients with significant comorbidities likely to 
receive IPT in the future, it is important to assess the impact of therapy in real-world 
cohorts, particularly in relation to adverse effects and treatment completion. Previous 
reports have tended to emphasize serious treatment limiting adverse effects, particularly 
hepatotoxicity, which has been well-studied in prospective cohorts.3 However, a wide 
variety of less well-documented adverse effects have been observed in association 
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with IPT, including acneiform and other rashes, gastrointes-
tinal adverse effects, peripheral neuropathy, drowsiness, and 
alopecia, many of which have been reported in case reports 
or series but not prospectively considered in a real-world 
cohort.4–7 The frequency with which many of these adverse 
effects occur is poorly defined, yet may have substantial 
impact on patient willingness to initiate or complete therapy, 
particularly as patients with LTBI are not symptomatic. We 
therefore aimed to prospectively study the adverse effects 
of IPT in a real-world cohort, and consider their frequency, 
severity and association with failure to complete therapy.
Methods
This study was approved by the Melbourne Health Human 
Research Ethics Committee as a quality assurance activity. 
The requirement for participant consent was waived, as all 
information was collected as part of routine clinical care.
From June 2011, all patients commencing treatment for LTBI 
at the Royal Melbourne Hospital were prospectively and 
sequentially enrolled in an ongoing database of LTBI treat-
ment outcomes, particularly related to adverse effects and 
treatment adherence. Routine clinical review was conducted 
via outpatient clinics at 0, 1, 3, 6, and 9 months for those 
receiving 9-month courses of 300 mg daily IPT, with liver 
function testing performed prior to commencement but not 
routinely thereafter, except for patients with existing liver dis-
ease or baseline liver function abnormalities.8 At each visit, 
medication was dispensed for patient self-administration, 
without direct observation. Pyridoxine supplementation was 
provided routinely for patients considered to be at risk of 
malnutrition. Patients were advised to abstain from alcohol. 
At the time of each visit, a standardized reporting form was 
completed by clinicians who recorded treatment adherence 
and the presence and severity of any adverse effects during 
the preceding period of therapy. Any adverse event was noted, 
including an assessment of its grade of severity according 
to the United Nations World Health Organization (WHO) 
Toxicity Grading Scale. Twelve months after initiation of 
IPT, an additional retrospective medical record review was 
performed to document treatment completion.
While alternative therapies for prevention of TB reacti-
vation were also prescribed at our health center, including 
4-month courses of rifampicin, this report presents data 
relating to the first 100 patients prescribed the most common 
regimen of a 9-month course of isoniazid therapy (93% of all 
prescriptions over the reported period; data not presented).
Standard counselling for IPT was provided to all 
patients prior to commencement. This included discussions 
of well-established potential adverse effects (particularly 
hepatitis, peripheral neuropathy, and allergic reactions); 
encouraging patients to report any potentially adverse effects; 
and provision of an information sheet about LTBI and its 
treatment.
Treatment completion for isoniazid was defined as 
receipt of the planned 9-month course within a 12-month 
period. It was pre-specified that descriptive analysis of 
outcomes would be conducted following the enrollment 
of 100 patients. This sample size was calculated to have 
more than 80% power (alpha =0.05) to detect side effects 
occurring with a frequency of 0.02 or greater in our cohort. 
Statistical calculations were performed in Microsoft Excel 
and StataCorp Stata 10. Fisher’s exact test or chi-squared 
tests with two-tailed P-values were performed for between-
group comparisons of dichotomous categories. In comparing 
continuous variables, t-tests were used.
Results
Demographic characteristics of the first 100 patients com-
menced on LTBI therapy are included in Table 1. The 
majority of patients were aged less than 35 years old, but 
12 patients were aged 35–50 years old and nine were aged 
over 50 years old. Twelve patients had abnormalities of liver 
function at initiation of therapy, including six with hepatitis 
B virus (HBV) infection.
Fifty-six patients reported at least one adverse effect at 
some stage during treatment. The number of patients report-
ing various adverse effects on at least one visit is presented in 
Table 2. The majority of adverse effects were Grade 1–2, with 
six patients experiencing at least one Grade 3–4 adverse effect 
Table 1 Demographic characteristics of study cohort
Factor Number
Male 58
age (median, range), years 29 (16–72)
region of birth
 indian subcontinent 38
  Asia–Pacific (excluding Australia) 36
 australia 14
 africa 7
 europe 4
 South america 1
comorbidities
 Hepatitis B 6
 Hepatitis c 0
 HiV 1
 liver disease (non-hepatitis) 6
 Diabetes 6
 renal disease 3
Abbreviation: HIV, human immunodeficiency virus.
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during therapy. Increased age was significantly associated 
with risk of adverse effects (odds ratio [OR] =1.05 per year; 
confidence interval [CI] of 1.02–1.08=95%). Sex was not 
associated with risk of adverse effects; neither were any 
comorbid factors such as HBV infection or pre-existing liver 
or renal disease. Despite this frequency of adverse events, 
the majority of patients with adverse effects successfully 
continued therapy, with 46/56 (82%) completing the planned 
course of treatment.
Of the first 100 patients started on 9-month courses of 
isoniazid, 85 patients successfully completed therapy in our 
health center. Three patients were transferred interstate, 
with documented arrangements to complete therapy. Twelve 
patients discontinued therapy, with ten citing adverse effects 
as the reason for treatment cessation and two patients failing 
to return for follow up. No hospitalizations or deaths occurred 
during the period of study. Of the 15 patients who did not 
complete treatment, no association with sex or age was found 
(P=0.51 and 0.78, respectively).
gastrointestinal and hepatitic  
adverse effects
The most common adverse effects overall were gastrointesti-
nal, reported by 21 patients at some time during their course. 
Gastrointestinal symptoms tended to be identified at the 
initiation of treatment and spontaneously resolve; however, 
two patients discontinued therapy because of persistent gas-
trointestinal symptoms.
The mean age of the five patients who developed hepa-
totoxicity was 35.2 years old, while the mean age of the 95 
patients who did not develop hepatotoxicity was 31.7 years 
(not significant). Only one patient experienced a Grade 3 or 
4 hepatitis, with an alanine transferase (ALT) peak of 1,268 
IU/L and bilirubin of 100 μmol/L approximately 4 months 
after starting therapy. This patient did not have pre-existing 
liver function test abnormalities or comorbidities at baseline. 
Isoniazid was ceased, with complete resolution of liver test 
abnormalities. The other four patients successfully completed 
treatment without interruption of therapy.
Dermatological adverse effects
Dermatological manifestations occurred in 15 patients, 
with eight patients developing acneiform rashes and eight 
patients developing generalized rashes (one patient experi-
enced both at different times during treatment). No patient 
reported alopecia. Interestingly, while age was not a predictor 
of overall risk of rash, when grouped as “acneiform” and 
“non- acneiform” this effect was seen, with 8/8 patients under 
35 years of age experiencing acne. One patient with pre-
existing acne developed a severe flare, for which isotretinoin 
was prescribed after failure of topical therapy.
neuropsychiatric adverse effects
The most common neuropsychiatric adverse effects reported 
were perceived cognitive impairment (nine patients) and 
lethargy (seven patients). A small number of patients 
reported headaches (two patients), sleep disturbance (one 
patient) and blurred vision (one patient). Four patients 
reported Grade 1 peripheral neuropathy, all relating to 
“pins and needles” and subjective sensory loss. One patient 
(of four) was receiving pyridoxine supplementation at the 
time of reporting symptoms. Three episodes were noted to 
occur late in therapy, with isoniazid discontinued as planned 
shortly thereafter. One episode occurred early in therapy, 
which resolved following introduction of pyridoxine. No 
association between peripheral neuropathy and sex or age 
was observed.
One patient experienced a transient psychosis 1 month 
after initiating isoniazid. The episode, marked by paranoia 
and hallucination, lasted approximately 1 week before spon-
taneously resolving, and was not reported until a subsequent 
clinic visit 2 months later. After discussion with the patient, 
treatment was continued without further incident.
Discussion
This report highlights a variety of somatic adverse effects 
that occurred in a real-world cohort of patients receiving IPT. 
While adverse effects were frequently identified in this study, 
the considerable majority of patients experienced low grade 
and transient effects. Importantly, despite observed adverse 
Table 2 adverse effects of isoniazid preventative therapy for 
latent tuberculosis infection
Adverse effect Number of  
patients
Grade 3–4 
severity
any adverse effect 56 6
any gastrointestinal 21 2
Hepatitis 5 1
any dermatologic 15 1
any rash 15 1
acne 8 1
alopecia 0 0
any neuropsychiatric 19 1
lethargy 7 0
cognitive impairment 9 0
Peripheral neuropathy 4 0
Headache 2 0
Sleep disturbance 1 0
Depression 1 0
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effects, this study has also demonstrated high levels of treat-
ment adherence and completion in our cohort.
Prospectively-collected data on adverse effects and treat-
ment completion are important for ensuring that patients are 
reasonably informed regarding the risks and benefits of isoni-
azid therapy. This is particularly the case given the increased 
range of age and comorbidities in real-world cohorts, as 
compared with those studied in many controlled trials.9
Variable (and frequently low) treatment completion 
rates have been reported in other cohorts receiving IPT, 
leading to concerns about the effectiveness of treatment 
as a preventative strategy.10,11 The findings from our cohort 
are reassuring in this regard, with 85% successful treatment 
completion demonstrated. This may reflect differences in 
our cohort, such as increased motivation due to perceived 
or actual high risk of contracting tuberculosis, or potential 
factors relating to routine pre-treatment counselling and fol-
low up. Effective strategies for supporting good adherence 
are important, and further research toward such approaches 
would be valuable.
Five patients were observed to have abnormalities of 
liver function testing during therapy. While higher frequency 
of hepatotoxicity is recognized in older patients receiving 
isoniazid, we would observe that 4/5 patients in our cohort 
experienced transient mild elevations which resolved without 
cessation of therapy.12
In some settings, pyridoxine (PN) supplementation is 
given routinely for prevention of PN deficiency during IPT; 
however, the benefit of doing so for patients not at high 
risk is poorly established. In our cohort, 75% of those who 
reported symptoms of PN deficiency were not on pyridoxine. 
No definitive diagnostic test for isoniazid-associated PN 
deficiency exists, and patients reporting any symptoms 
potentially associated with PN deficiency were included in 
our report; the 4% of patients with symptoms is therefore 
likely to overestimate the risk.
Among adverse effects reported by patients, the fre-
quency of lethargy and cognitive impairment was surpris-
ing, affecting 7 and 9 patients, respectively. While these 
 symptoms tended to be mild, they were noticeable for 
patients. Information regarding adverse cognitive effects had 
not previously formed part of our routine counselling prior 
to this study, thus future guidelines will reflect increased 
recognition of these symptoms.
As IPT is used more widely and for increasingly broad 
indications, treatment guidelines should include realistic 
information on the frequency and severity of potential 
adverse effects. This information should be used to guide 
individuals and prescribing clinicians in making rational deci-
sions about the risks and benefits of therapy, and should also 
include realistic plans for dealing with adverse effects, such 
as symptomatic strategies and alternatives for those unable 
to tolerate therapy. Overall, however, our experience has been 
that the majority of adverse effects are mild and transient, 
even in cohorts of older patients with comorbidities.
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